Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 13/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19991547 | 0.81 | WDR5 (0.64) | WDR5LMNANPC1RAB9AHTT | |
| SCHEMBL19991561 | 0.76 | WDR5 (0.53) | WDR5LMNANPC1RAB9AHTT | |
| SCHEMBL19997719 | 0.75 | WDR5 (0.84) | WDR5 | |
| SCHEMBL19991502 | 0.74 | WDR5 (0.74) | WDR5 | |
| SCHEMBL19991538 | 0.72 | WDR5 (0.59) | WDR5LMNANPC1RAB9AHTT | |
| SCHEMBL19991539 | 0.71 | WDR5 (0.62) | WDR5LMNANPC1RAB9AHTT | |
| SCHEMBL3440357 | 0.70 | LMNA (0.67) | WDR5LMNANPC1RAB9AHTT | |
| SCHEMBL19991519 | 0.70 | WDR5 (0.62) | WDR5LMNANPC1RAB9AHTT | |
| SCHEMBL19991550 | 0.68 | WDR5 (0.44) | WDR5LMNANPC1RAB9AHTT | |
| SCHEMBL9988367 | 0.68 | NCF1 (0.56) | LMNAHTTGAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160763-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180086767-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086767-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR77 | WDR5 1/4885LMNA 2637/4885NPC1 1121/4885 |
| US-10160763-B2 | WDR5 inhibitors and modulators | WDR5, WDR1, WDR77 | WDR5 1/4885LMNA 2637/4885NPC1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.